# The Royal Marsden

Source: https://nuclide.cc/institutions/royal-marsden/  
Nuclide record `royal-marsden` (Institution). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

The Royal Marsden was the world's first hospital dedicated to cancer (1851) and is paired with the Institute of Cancer Research.

## Summary

The Royal Marsden in London was the world's first hospital dedicated to cancer, opened in 1851, and works as a pair with The Institute of Cancer Research; it ranks seventh in the Newsweek/Statista oncology list. Together they discovered abiraterone and worked out the clinical path for olaparib and PARP inhibition in BRCA-mutated cancers, with Johann de Bono and Andrew Tutt central, and the hospital leads the STAMPEDE prostate platform and breast trials while pioneering MR-linac adaptive radiotherapy. Nuclide links it to the KEYNOTE-048 head and neck paper, to prostate, mesothelioma, sarcoma and neuroendocrine tumour pages, and to bottlenecks about surgery and radiotherapy being under-funded relative to drugs. The question it keeps raising is how to fund trials of treatments no company owns. Stephen Johnston and James Larkin are among the people listed here.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: London, GB
- Type: cancer-center
- Website: https://www.royalmarsden.nhs.uk

## Sources

- Official website: https://www.royalmarsden.nhs.uk

## Connected records

- drugs: [Abiraterone acetate](https://nuclide.cc/drugs/abiraterone/), [Olaparib](https://nuclide.cc/drugs/olaparib/)
- indications: [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- trials: [STAMPEDE](https://nuclide.cc/trials/stampede/)
- people: [Chris C. Parker](https://nuclide.cc/people/chris-parker/)

---
JSON: https://nuclide.cc/api/v1/entities/royal-marsden.json